Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA.

Brain. 2009 Nov;132(Pt 11):2958-69. doi: 10.1093/brain/awp245. Epub 2009 Oct 7.

PMID:
19812213
2.

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ; ICICLE-PD study group, Barker RA.

Brain. 2014 Oct;137(Pt 10):2743-58. doi: 10.1093/brain/awu201. Epub 2014 Jul 30.

3.

APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Paul KC, Rausch R, Creek MM, Sinsheimer JS, Bronstein JM, Bordelon Y, Ritz B.

J Parkinsons Dis. 2016 Apr 2;6(2):349-59. doi: 10.3233/JPD-150762.

4.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

5.

Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals.

Winder-Rhodes SE, Hampshire A, Rowe JB, Peelle JE, Robbins TW, Owen AM, Barker RA.

Neurobiol Aging. 2015 Mar;36(3):1519-28. doi: 10.1016/j.neurobiolaging.2014.12.006. Epub 2014 Dec 11.

6.

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA.

Brain. 2007 Jul;130(Pt 7):1787-98. Epub 2007 May 29. Review.

PMID:
17535834
7.

The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia.

Samaranch L, Cervantes S, Barabash A, Alonso A, Cabranes JA, Lamet I, Ancín I, Lorenzo E, Martínez-Lage P, Marcos A, Clarimón J, Alcolea D, Lleó A, Blesa R, Gómez-Isla T, Pastor P.

J Alzheimers Dis. 2010;22(4):1065-71. doi: 10.3233/JAD-2010-101011.

PMID:
20930301
8.

Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.

Williams-Gray CH, Hampshire A, Barker RA, Owen AM.

Brain. 2008 Feb;131(Pt 2):397-408. doi: 10.1093/brain/awm313. Epub 2008 Jan 4.

PMID:
18178571
9.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

10.

Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.

Bäckström D, Eriksson Domellöf M, Granåsen G, Linder J, Mayans S, Elgh E, Zetterberg H, Blennow K, Forsgren L.

Acta Neurol Scand. 2018 Jan;137(1):91-98. doi: 10.1111/ane.12812. Epub 2017 Sep 4.

11.

Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.

Zhang Y, Feng S, Nie K, Zhao X, Gan R, Wang L, Zhao J, Tang H, Gao L, Zhu R, Wang L, Zhang Y.

J Neurol Sci. 2016 Oct 15;369:347-353. doi: 10.1016/j.jns.2016.08.063. Epub 2016 Aug 31.

PMID:
27653922
12.

The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.

Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA.

Brain. 2012 Aug;135(Pt 8):2449-57. doi: 10.1093/brain/aws157.

PMID:
22843413
13.

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease.

Hoogland J, de Bie RM, Williams-Gray CH, Muslimović D, Schmand B, Post B.

Mov Disord. 2010 Nov 15;25(15):2550-4. doi: 10.1002/mds.23319.

PMID:
20878993
14.

Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.

Hobson P, Meara J.

Int J Geriatr Psychiatry. 2015 Oct;30(10):1048-55. doi: 10.1002/gps.4261. Epub 2015 Feb 11.

PMID:
25676160
15.

H1/H2 MAPT haplotype and Parkinson's disease in Mexican mestizo population.

Miranda-Morales EG, Sandoval-Carrillo A, Castellanos-Juárez FX, Méndez-Hernández EM, La Llave-León O, Quiñones-Canales G, Ruano-Calderón LA, Arias-Carrión O, Salas-Pacheco JM.

Neurosci Lett. 2019 Jan 18;690:210-213. doi: 10.1016/j.neulet.2018.10.029. Epub 2018 Oct 16.

PMID:
30339920
16.

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.

Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA.

J Neurosci. 2007 May 2;27(18):4832-8.

17.

Role of ethnicity on the association of MAPT H1 haplotypes and subhaplotypes in Parkinson's disease.

Winkler S, König IR, Lohmann-Hedrich K, Vieregge P, Kostic V, Klein C.

Eur J Hum Genet. 2007 Nov;15(11):1163-8. Epub 2007 Jul 18.

18.

Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.

Lin CH, Fan JY, Lin HI, Chang CW, Wu YR.

Parkinsonism Relat Disord. 2018 May;50:48-53. doi: 10.1016/j.parkreldis.2018.02.015. Epub 2018 Feb 9.

19.

Role of the H1 haplotype of microtubule-associated protein tau (MAPT) gene in Greek patients with Parkinson's disease.

Refenes N, Bolbrinker J, Tagaris G, Orlacchio A, Drakoulis N, Kreutz R.

BMC Neurol. 2009 Jun 28;9:26. doi: 10.1186/1471-2377-9-26.

20.

Tau haplotypes regulate transcription and are associated with Parkinson's disease.

Kwok JB, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, Buchanan DD, Silburn PA, Schofield PR.

Ann Neurol. 2004 Mar;55(3):329-34.

PMID:
14991810

Supplemental Content

Support Center